Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefazolin sodium, quantity: 1.048 g - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: - respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present; - genitourinary tract infections due to e. coli, p. mirabilis, klebsiella sp. and some strains of enterobacter and enterococci; - skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resistant), and group a beta-haemolytic streptococci and other strains of streptococci; - bone and joint infections due to staph. aureus; - septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), p. mirabilis, e. coli and klebsiella sp.; - endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefazolin sodium, quantity: 0.524 g - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: - respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present; - genitourinary tract infections due to e. coli, p. mirabilis, klebsiella sp. and some strains of enterobacter and enterococci; - skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resistant), and group a beta-haemolytic streptococci and other strains of streptococci; - bone and joint infections due to staph. aureus; - septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), p. mirabilis, e. coli and klebsiella sp.; - endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefazolin sodium, quantity: 1048 mg (equivalent: cefazolin, qty 1000 mg) - injection, powder for - excipient ingredients: - cephazolin sodium injection is indicated in the treatment of the following serious infections due to susceptible organisms: 1. respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin sodium is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin sodium in the subsequent prevention of rheumatic fever are not available at present 2. gentinourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species and some strains of enterobacter and enterococci. 3. skin and soft-tissue infections due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci and other strains of streptococci. 4. bone and joint infections due to staph. aureus. 5. septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin- resistant), pr. mirabilia, esch. coli and klebsiella species. 6. endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cephazolin sodium.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefazolin sodium, quantity: 524 mg (equivalent: cefazolin, qty 500 mg) - injection, powder for - excipient ingredients: - cephazolin sodium injection is indicated in the treatment of the following serious infections due to susceptible organisms: 1. respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin sodium is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin sodium in the subsequent prevention of rheumatic fever are not available. 2. gentinourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species and some strains of enterobacter and enterococci. 3. skin and soft-tissue infections due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci and other strains of streptococci. 4. bone and joint infections due to staph. aureus. 5. septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin- resistant), pr. mirabilia, esch. coli and klebsiella species. 6. endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cephazolin sodium.

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - cefazolin sodium 2.096 g equivalent to cefazolin 2 g;   - powder for injection - 2 g - active: cefazolin sodium 2.096 g equivalent to cefazolin 2 g  

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin 500 mg in 2.2 ml - cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, and other strains of

United States - English - NLM (National Library of Medicine)

cardinal health - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin 330 mg in 1 ml - cefazolin for injection, usp is indicated in the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, and other strains of stre

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin 1 g in 3 ml - cefazolin for injection, usp is indicated for the treatment of the following serious infections when due to susceptible organisms. respiratory tract infections: due to s. pneumoniae,   klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic st

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefazolin sodium 524mg equivalent to 500 mg cefazolin - powder for injection - 500 mg - active: cefazolin sodium 524mg equivalent to 500 mg cefazolin - cefazolin-aft is indicated in the treatment of the following serious infections due to susceptible organisms: respiratory tract infection: due to s. pneumoniae, klebsiella sp, h. influenzae, staph, aureus (including penicillinase-producing strains), and group a ?-haemolytic streptococci. injectable penicillin g benzathine is considered to be the medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin-aft is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin in the subsequent prevention of rheumatic fever are not available at present.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefazolin sodium, quantity: 2.097 mg - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: ? respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. ? genitourinary tract infections due to e. coli, p. mirabilis, klebsiella sp. and some strains of enterobacter and enterococci. ? skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci and other strains of streptococci. ? bone and joint infections due to staph. aureus. ? septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), p. mirabilis, e. coli and klebsiella sp. ? endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. ? appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin